title: Quest for the best.
abstract: By combining innovative science with years of massive investment, drug makers seek to turn newly discovered chemicals into revolutionary blockbuster drugs that generate billions of dollars in revenue. So every year, they collectively spend tens of billions of dollars on the high-risk pursuit of the next Prozac or Viagra. But should they? This article analyses key themes around differentiation that we have found to be common among blockbusters, and examines the implications for creating future billion-dollar drugs.
authors.affiliation: McKinsey & Company's New York Office at 55 East 52nd Street 21st Floor, New York, New York, 10055, USA. Bruce_Booth@McKinsey.com
authors.forename: Bruce
authors.initials: B
authors.lastname: Booth
authors.forename: Rodney
authors.initials: R
authors.lastname: Zemmel
mesh_terms: D017277:Drug Approval; D016527:Drug Costs / Q000639:trends*; D015195:Drug Design; D004341:Drug Evaluation; D004345:Drug Industry / Q000191:economics*; D006801:Humans; D012449:Safety; D016896:Treatment Outcome